NORTH BRUNSWICK, N.J. and NANJING, China, Sept. 3 /PRNewswire/ -- Acesys Pharmatech and Provid Pharmaceuticals Inc. announce a strategic alliance, combining the drug discovery expertise and project management capabilities of Provid in the US with the medicinal chemistry resources and favorable cost structure of Acesys in China.
The combined services available through the alliance will encompass all aspects of medicinal chemistry for clients in the pharmaceutical and biotech industries.
An experienced team at Provid will be involved in the design of programs, in the creation of novel intellectual property, and in exploratory research. Acesys will provide support for these projects with scaffold construction, hit-to-lead exploration, focused library synthesis, analog synthesis and other aspects of drug discovery.
Each project will operate via an alliance team including scientists and a program leader from Provid, a senior team leader and medicinal chemists from Acesys, and the client's representatives. Blending the US and China efforts will enable clients to benefit from the combined experience, emphasis on high quality, productivity, and sophisticated science, coupled with lower costs.
"We have explored opportunities for alliances with emerging companies in China for some time," said Dr. Gary Olson, Provid CEO, "and have been impressed by the exceptionally well-qualified and experienced drug discovery chemists that lead the Acesys organization. They have many years of successful CRO experience serving international pharmaceutical and biotech companies."
"With Provid's years of experience in medicinal chemistry and project
management, Acesys will be able to provide low-cost medicinal chemistry
service with uniquely high quality and high productivity," said Charles Ye,
CEO and President of Acesys Pharmatech, "Provid has proved its expertise in
medicinal chemistry in numerous projects, and has a great track record. The
|SOURCE Provid Pharmaceuticals Inc.|
Copyright©2008 PR Newswire.
All rights reserved